Vertex Pharmaceuticals Inc (VRTX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$5.79 (-1.22%)Past Day

About

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Key Insights

  • Share Price

    $467.85

  • Market Cap

    $120.75 Billion

  • Total Outstanding Shares

    258.10 Million Shares

  • Total Employees

    5,400

  • Dividend

    No dividend

  • IPO Date

    July 31, 1991

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.vrtx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2023 to June 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$-944.00 Million
Net Cash Flow$-5.56 Billion
Exchange Gains/Losses$-13.20 Million
Net Cash Flow From Financing Activities, Continuing$-1.00 Billion
Net Cash Flow From Investing Activities, Continuing$-3.60 Billion
Net Cash Flow From Financing Activities$-1.00 Billion
Net Cash Flow, Continuing$-5.55 Billion
Net Cash Flow From Operating Activities$-944.00 Million
Net Cash Flow From Investing Activities$-3.60 Billion

Income Statement

July 1, 2023 to June 30, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Available To Common Stockholders, Basic$-489.90 Million
Selling, General, and Administrative Expenses$1.35 Billion
Basic Average Shares$516.10 Million
Basic Earnings Per Share$1.89
Income/Loss From Continuing Operations Before Tax$214.70 Million
Operating Income/Loss$-348.60 Million
Diluted Earnings Per Share$1.98
Costs And Expenses$10.69 Billion
Cost Of Revenue$1.40 Billion
Diluted Average Shares$518.80 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Operating Expenses$9.28 Billion
Other Operating Expenses$7.94 Billion
Income/Loss From Continuing Operations After Tax$-489.90 Million
Benefits Costs and Expenses$10.12 Billion
Income Tax Expense/Benefit$704.60 Million
Net Income/Loss Attributable To Parent$-489.90 Million
Gross Profit$8.94 Billion
Revenues$10.34 Billion
Net Income/Loss$-489.90 Million

Balance Sheet

July 1, 2023 to June 30, 2024
MetricValue
Liabilities And Equity$20.13 Billion
Other Current Assets$8.03 Billion
Current Assets$8.94 Billion
Noncurrent Liabilities$1.81 Billion
Inventory$914.60 Million
Assets$20.13 Billion
Current Liabilities$3.55 Billion
Noncurrent Assets$11.19 Billion
Accounts Payable$327.90 Million
Commitments and Contingencies$0.00
Other Non-current Assets$10.35 Billion
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$14.77 Billion
Liabilities$5.36 Billion
Equity$14.77 Billion
Other Current Liabilities$3.22 Billion
Intangible Assets$837.50 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
News ArticlesAbout UsPrivacy Policy & Cookies Information

ⓒ2024 Financhle. All Rights Reserved.